List of Excipients in Branded Drug ULTRACET

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Rebel Distributors Corp	ULTRACET	tramadol hydrochloride and acetaminophen	21695-143	CARNAUBA WAX
Rebel Distributors Corp	ULTRACET	tramadol hydrochloride and acetaminophen	21695-143	FERRIC OXIDE RED
Rebel Distributors Corp	ULTRACET	tramadol hydrochloride and acetaminophen	21695-143	HYPROMELLOSES
Rebel Distributors Corp	ULTRACET	tramadol hydrochloride and acetaminophen	21695-143	MAGNESIUM STEARATE
Rebel Distributors Corp	ULTRACET	tramadol hydrochloride and acetaminophen	21695-143	POLYETHYLENE GLYCOL
Rebel Distributors Corp	ULTRACET	tramadol hydrochloride and acetaminophen	21695-143	POLYSORBATE 80
Rebel Distributors Corp	ULTRACET	tramadol hydrochloride and acetaminophen	21695-143	POWDERED CELLULOSE

ULTRACET Excipient Strategy, Patent Position and Commercial Opportunities

Last updated: October 7, 2026

ULTRACET is an immediate-release fixed-dose combination of tramadol hydrochloride 37.5 mg and acetaminophen 325 mg. Its core US commercial opportunity is generic supply, lifecycle reformulation and international commercialization rather than restoration of branded exclusivity. Excipient differentiation can improve manufacturability, tablet robustness, dissolution, taste and abuse-resistance, but it does not create a new product category without supporting clinical, bioequivalence and regulatory evidence.

What is ULTRACET and how is it formulated?

ULTRACET combines an opioid analgesic with a non-opioid analgesic in a single immediate-release tablet.

Attribute	ULTRACET specification
Active ingredients	Tramadol hydrochloride 37.5 mg; acetaminophen 325 mg
Dosage form	Immediate-release tablet
Original US sponsor	Ortho-McNeil Pharmaceutical, later associated with Janssen
US regulatory application	NDA 020281
Initial FDA approval	2001
Standard dosing	One or two tablets every four to six hours as needed
Maximum labeled daily dose	Eight tablets
Maximum daily actives at labeled limit	Tramadol 300 mg; acetaminophen 2,600 mg
Therapeutic category	Acute and short-term pain management
Controlled-substance status	Tramadol is a Schedule IV controlled substance in the United States
Current competitive products	Multiple generic tramadol/acetaminophen tablets

At the maximum labeled dose, the product delivers 2,600 mg of acetaminophen daily. The label warns against use with other acetaminophen-containing products and identifies risks associated with tramadol, including respiratory depression, misuse, dependence, seizures and serotonin syndrome.[1]

The reference formulation uses conventional tablet excipients, including microcrystalline cellulose, corn starch, hypromellose, magnesium stearate, povidone, sodium starch glycolate, colloidal silicon dioxide and titanium dioxide.[1] These materials support powder flow, compression, tablet breakup, lubrication and film coating.

What excipients are used in ULTRACET tablets?

The existing excipient platform is conventional and relatively accessible to generic manufacturers. That reduces formulation barriers but leaves room for process and performance differentiation.

Microcrystalline cellulose and starch systems

Microcrystalline cellulose contributes compactibility and tablet hardness. Corn starch and sodium starch glycolate support disintegration. The combination is suitable for an immediate-release tablet that must release both tramadol and acetaminophen promptly.

A generic manufacturer can alter the ratio of filler to disintegrant to improve:

• Tablet tensile strength
• Disintegration time
• Dissolution consistency
• Compression speed
• Sensitivity to humidity
• Weight variation
• Friability

The key development risk is balancing mechanical strength with rapid disintegration. Excessive compression force or lubricant can slow dissolution, while excessive disintegrant can weaken tablets and complicate high-speed production.

Povidone and silicon dioxide

Povidone can function as a binder in wet granulation and can improve granule strength. Colloidal silicon dioxide improves flow and may reduce sticking during compression.

A direct-compression process could reduce manufacturing steps and solvent exposure. Wet granulation may provide better content uniformity and compression performance when the active ingredients have different particle-size distributions or flow properties.

Magnesium stearate

Magnesium stearate is a conventional lubricant but can produce dissolution variability if overmixed. Lubricant concentration, blending time and shear are important process parameters. A generic manufacturer seeking robust dissolution data should control the lubrication step tightly and assess its effect on both active ingredients.

Film coating

Hypromellose-based coating can improve swallowability, reduce dusting and provide color identification. Titanium dioxide contributes opacity and appearance. A coating change normally has limited clinical significance if it does not materially affect dissolution, stability or bioequivalence.

What excipient strategy offers the strongest commercial opportunity?

The strongest opportunity is a robust, low-cost immediate-release platform rather than a complex new delivery system.

Strategy	Commercial value	Regulatory burden	Main risk
Conventional generic tablet	High volume, low differentiation	ANDA bioequivalence	Price erosion
Improved direct-compression tablet	Lower manufacturing cost	Moderate CMC and BE work	Dissolution variability
Moisture-protected formulation	Useful for tropical markets	Moderate stability package	Packaging cost
Taste-masked tablet	Useful for selected patient groups	Moderate to high	Masking can delay release
Abuse-deterrent formulation	Potential differentiation	High	Tramadol and combination-product evidence requirements
Extended-release formulation	New dosing proposition	High, often NDA or 505(b)(2)	Different exposure and safety profile
Sprinkle or orally disintegrating tablet	Administration convenience	Moderate to high	Dose uniformity and palatability
Pediatric formulation	Limited but specialized market	High	Pediatric safety and dosing requirements

A low-cost immediate-release tablet has the clearest commercial case because it remains aligned with the established clinical use and reference-product performance. A manufacturer can improve value through consistent dissolution, lower defect rates, longer stability and better packaging without changing the pharmacological proposition.

What patent protection covers ULTRACET?

The original ULTRACET patent estate no longer provides a meaningful barrier to US generic entry. The principal combination concept, involving tramadol and acetaminophen in an analgesic composition, was disclosed and patented before the product’s 2001 approval. The relevant patent terms expired before the current generic market matured.

The commercial protection profile is therefore different from that of a recently approved branded medicine:

Protection category	ULTRACET position
Active-ingredient patents	Expired or commercially nonblocking
Original combination patents	Expired
Regulatory exclusivity	Expired
Orange Book strategy	No effective current barrier to standard generic entry
Formulation patents	No widely recognized active formulation barrier defining the US market
Method-of-use patents	Not a material barrier to standard tramadol/acetaminophen tablets
Trade-secret protection	Potentially relevant to manufacturing process, not generic product entry
Trademark protection	Relevant to branding, not substitution by ANDA products

The key intellectual-property opportunity is a new formulation, manufacturing process or delivery system with distinct claims. Repackaging the same immediate-release formulation with routine excipient substitutions is unlikely to support a durable patent position unless the formulation produces a measurable technical effect.

What is the Orange Book status of ULTRACET?

ULTRACET’s original FDA approval was under NDA 020281. Because the product has long been exposed to generic competition, an applicant can generally pursue an abbreviated new drug application for the same active ingredients, strength, dosage form and route of administration.

An ANDA applicant must address listed patents, if any, through the applicable certification pathway. For an old combination product with expired patent protection, the principal route is normally a paragraph III certification for expired patents or a paragraph I certification where no relevant patent information remains listed.[2]

The Orange Book does not grant ongoing exclusivity merely because a brand name remains recognized in the market. A reformulated product with a new excipient system may require a separate regulatory pathway if it changes dosage form, release characteristics, clinical performance or labeling.

When did ULTRACET lose exclusivity?

ULTRACET lost practical US market exclusivity after expiration of its original patent and regulatory protection. Generic tramadol/acetaminophen products entered the US market years ago, and the product is no longer protected by the type of exclusivity associated with a newly launched branded combination.

The commercial consequence is significant:

1. A generic manufacturer does not need to license the ULTRACET brand.
2. Routine excipient substitutions can be evaluated under the ANDA framework.
3. The main competitive variables are price, supply reliability, manufacturing quality and customer contracts.
4. A differentiated formulation must establish a new regulatory and intellectual-property position.

Which companies are challenging or competing with ULTRACET?

The US market includes generic manufacturers and distributors offering tramadol hydrochloride/acetaminophen tablets. Competition is generally fragmented and includes large generic companies, contract manufacturers and specialty suppliers.

The principal competitive groups are:

• Large diversified generic manufacturers
• US-based specialty pharmaceutical companies
• Indian generic manufacturers
• Contract development and manufacturing organizations
• Regional distributors supplying institutional and retail channels

No biosimilar pathway applies. ULTRACET is a small-molecule combination product, not a biologic. Competitive risk comes from ANDA products and potentially from alternative analgesics, including tramadol alone, nonsteroidal anti-inflammatory drugs, acetaminophen alone, opioid combinations and newer non-opioid pain products.

What formulation patents could protect a new ULTRACET product?

A new formulation patent would need claims directed to a specific technical solution rather than a routine excipient swap.

Potential claim areas include:

Abuse-deterrent formulation

A polymer matrix, gelling system or chemically modified dosage form could make crushing, extraction or rapid release more difficult. FDA guidance recognizes several abuse-deterrence technologies, including physical and chemical barriers, agonist-antagonist systems, aversion systems and delivery-system controls.[3]

For tramadol/acetaminophen, development is complicated by the need to control two actives with different physicochemical properties. An abuse-deterrent design must avoid creating excessive acetaminophen release while also preserving acceptable tramadol exposure.

Modified-release combination

An extended-release dosage form could reduce dosing frequency. This would not be a simple generic substitution because altered release changes pharmacokinetics and may require a new drug application or 505(b)(2) pathway.

The development case is commercially weaker than for some chronic pain products because tramadol carries opioid-related safety concerns and the combination is commonly used for acute pain. A new extended-release product would face clinical, labeling and post-market requirements.

Orally disintegrating or taste-masked tablet

An orally disintegrating tablet could target patients with dysphagia. Taste masking is difficult because both tramadol and acetaminophen can create unpleasant sensory profiles. Ion-exchange resins, polymer coatings, lipid barriers and multiparticulate systems are possible approaches.

The formulation must maintain rapid release and demonstrate dose uniformity. A taste-masking claim is more valuable if it enables a clinically meaningful administration advantage.

Moisture-stable formulation

A formulation that maintains dissolution and assay under high humidity could support international markets with less sophisticated storage infrastructure. The patent position would be stronger if it linked a defined excipient ratio or manufacturing condition to a measurable stability improvement.

What manufacturing and IP barriers affect commercial entry?

The active ingredients are established and widely available, so raw-material access is not the principal barrier. The main barriers are manufacturing quality, regulatory compliance and commercial scale.

Important technical controls include:

• Separate control of tramadol and acetaminophen assay
• Uniform distribution of both actives
• Control of particle-size differences
• Lubrication time and magnesium stearate exposure
• Dissolution in multiple media
• Tablet hardness and friability
• Moisture protection
• Packaging compatibility
• Controlled-substance inventory and security
• Stability through the proposed shelf life

Tramadol’s controlled-substance status increases recordkeeping, inventory-control and distribution requirements. The product also requires careful labeling and pharmacovigilance because acetaminophen toxicity and opioid-related risks arise from different components of the same tablet.[1]

Manufacturing know-how may create a practical advantage even when no blocking patent exists. Examples include a high-throughput direct-compression process with low weight variability, a granulation method that improves content uniformity or a coating process that reduces defects.

What generic launch scenarios exist for ULTRACET?

Low-cost standard generic

This is the most probable and lowest-risk model. The manufacturer matches the reference product’s strength, dosage form and release profile, then competes through cost, supply continuity and channel access.

Premium generic with manufacturing differentiation

A supplier may charge a modest premium for stronger supply assurance, longer dating, tamper-evident packaging or improved performance in institutional procurement. The premium will be limited because buyers can substitute among several immediate-release products.

International private-label product

Markets outside the United States may offer opportunities where branded tramadol/acetaminophen combinations retain stronger recognition or where local competitors are limited. Registration requirements, controlled-substance rules and country-specific opioid restrictions vary materially.

505(b)(2) lifecycle product

A new delivery system could support a 505(b)(2) application, but development costs and clinical obligations would be higher. The strongest candidates would provide a clear benefit such as reduced dosing frequency, improved administration or a validated abuse-deterrent property.

What licensing deals are relevant to ULTRACET?

The original branded product was associated with Ortho-McNeil and the broader Janssen commercial organization. No current licensing arrangement is required to sell a standard US generic version of tramadol/acetaminophen.

Potential licensing opportunities would involve:

• A novel abuse-deterrent platform
• A controlled-release technology
• A pediatric or orally disintegrating dosage form
• Regional rights for markets with limited competition
• A contract manufacturing or private-label supply agreement

A license is more commercially defensible when it conveys technology, regulatory data or market access. A license limited to the expired ULTRACET brand concept would have little value for a US generic entrant.

How strong is the ULTRACET patent estate?

The patent estate is weak as a barrier to standard generic entry and potentially useful only as a starting point for lifecycle development.

Factor	Assessment
Blocking patent risk	Low for conventional immediate-release generics
Formulation freedom	High for routine excipient substitutions
New-product patent potential	Moderate for validated delivery or abuse-deterrent systems
Regulatory complexity	Moderate for standard generics; high for modified release
Manufacturing barrier	Moderate
Commercial price pressure	High
Supply-chain opportunity	Moderate
Biosimilar risk	Not applicable

The best opportunity is operational rather than exclusionary: reliable supply, efficient compression, controlled-substance compliance and differentiated packaging.

Key Takeaways

• ULTRACET contains tramadol hydrochloride 37.5 mg and acetaminophen 325 mg in an immediate-release tablet.
• Its original US patent and exclusivity position no longer blocks generic competition.
• Conventional excipients support a low-cost generic strategy, with the greatest value in process robustness and dissolution control.
• A new excipient system can support patent protection only when it produces a defined technical benefit.
• Abuse-deterrent, orally disintegrating and modified-release products offer differentiation but carry materially higher regulatory risk.
• ULTRACET has no biosimilar exposure because it is a small-molecule combination product.
• The strongest commercial opportunities are generic supply, international private-label sales, manufacturing partnerships and targeted lifecycle reformulation.
• Standalone branded revenue is not a reliable valuation basis because public disclosures generally do not separate ULTRACET sales from broader analgesic portfolios.

FAQs

Can a manufacturer change ULTRACET excipients without changing the active ingredients?

Yes. An ANDA may use different inactive ingredients if the product remains pharmaceutically equivalent, meets quality standards and demonstrates bioequivalence and acceptable dissolution.

Is tramadol/acetaminophen eligible for a biosimilar application?

No. Biosimilar applications apply to biological products. Tramadol/acetaminophen is a small-molecule combination evaluated through generic or applicable new-drug pathways.

Can a new ULTRACET formulation receive new patents?

Yes, but a patent would need to claim a novel and non-obvious formulation, delivery system, manufacturing process or technical effect. Routine substitution of one filler or lubricant is unlikely to provide strong protection.

Does the acetaminophen component reduce the commercial value of an abuse-deterrent tramadol product?

It can. The formulation must control abuse-related tramadol release while preventing excessive acetaminophen exposure. That dual-ingredient requirement increases development and testing complexity.

Is an extended-release tramadol/acetaminophen product a straightforward generic opportunity?

No. Extended release changes exposure and dosing behavior. It generally requires a more extensive regulatory program than a conventional immediate-release ANDA and may require new clinical and pharmacokinetic evidence.

References

1. U.S. Food and Drug Administration. (2023). ULTRACET (tramadol hydrochloride and acetaminophen) tablets, prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2015). Guidance for industry: Abuse-deterrent opioids: Evaluation and labeling.
4. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs, NDA 020281.